The dog that did not bark: malaria vaccines without antibodies

Trends in Parasitology

Volumn 23, Issue 7, 2007, Pages 293-296

  Heppner, D Gray ^a   Schwenk, Robert J ^a   Arnot, David ^b   Sauerwein, Robert W ^c   Luty, Adrian J F ^c  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; MALARIA VACCINE; MULTIEPITOPE THROMBOSPONDIN RELATED ADHESIVE PROTEIN; PARASITE ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; CELLULAR IMMUNITY; DRUG MECHANISM; FOWLPOX VIRUS; FOWLPOX VIRUS 9; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; MALARIA; MEROZOITE; MODIFIED VACCINIA VIRUS ANKARA; NONHUMAN; PLASMODIUM FALCIPARUM; SHORT SURVEY; SPOROZOITE; T LYMPHOCYTE; VACCINIA VIRUS;

ANIMALS; ANTIBODIES, PROTOZOAN; CLINICAL TRIALS, PHASE II; FOWLPOX VIRUS; HUMANS; IMMUNOLOGIC MEMORY; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; VACCINES, DNA;

CANIS FAMILIARIS;

EID: 34250613123     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2007.05.002     Document Type: Short Survey

References (31)

1. Woodland D.L. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 25 (2004) 98-104
2. Dunachie S.J., et al. DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun. 74 (2006) 5933-5942
3. Gilbert S.C., et al. A protein particle vaccine containing multiple malaria epitopes. Nat. Biotechnol. 15 (1997) 1280-1284
4. McConkey S.J., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9 (2003) 729-735
5. Moorthy V.S., et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 1 (2004) e33
6. Bejon P., et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. 191 (2005) 619-626
7. Keating S.M., et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 175 (2005) 5675-5680
8. Vuola J.M., et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. 174 (2005) 449-455
9. Webster D.P., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 4836-4841
10. Bejon P., et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 24 (2006) 4709-4715
11. Bejon P., et al. Phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS. Clin. Trials 1 (2006) e29
12. Bejon P., et al. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin. Infect. Dis. 42 (2006) 1102-1110
13. Dunachie S.J., et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 24 (2006) 2850-2859
14. Imoukhuede E.B., et al. Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. Vaccine 24 (2006) 6526-6533
15. Walther M., et al. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect. Immun. 74 (2006) 2706-2716
16. Webster D.P., et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24 (2006) 3026-3034
17. Pouniotis D.S., et al. A new boost for malaria vaccines. Trends Parasitol. 20 (2004) 157-160
18. Wang R., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 (1998) 476-480
19. Graves, P. and Gelband, H. (2006) Vaccines for preventing malaria (pre-erythrocytic). Cochrane Database Syst. Rev. 4, CD006198
20. Stewart V.A., et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 24 (2006) 6483-6492
21. Girard M.P., et al. A review of human vaccine research and development: malaria. Vaccine 25 (2007) 567-580
22. Stoute J.A., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336 (1997) 86-91
23. Kester K.E., et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 183 (2001) 640-647
24. Stewart V.A., et al. Priming with an adenovirus 35-CS vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to P. falciparum CS over either malaria vaccine alone. Infect. Immun (2007). http://iai.asm.org/ 10.1128/IAI.01879-06 (http://iai.asm.org/)
25. Ballou W.R., et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet i (1987) 1277-1281
26. Herrington D.A., et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328 (1987) 257-259
27. Hoffman S.L., et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am. J. Trop. Med. Hyg. 51 (1994) 603-612
28. Bojang K.A., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (2001) 1927-1934
29. Zanetti M., and Franchini G. T cell memory and protective immunity by vaccination: is more better?. Trends Immunol. 27 (2006) 511-517
30. Schluns K.S., and Lefrancois L. Cytokine control of memory T cell development and survival. Nat. Rev. Immunol. 3 (2003) 269-279
31. Li S., et al. Viral vectors for malaria vaccine development. Vaccine 25 (2007) 2567-2574